Meta-Analyses [A]

Extended-Release Methylphenidate for Adult ADHD: What a Cochrane Review Found

A Cochrane systematic review asked whether extended-release methylphenidate helps adults diagnosed with ADHD. It included 24 randomised, double-blind, parallel-group trials (5066 participants), mostly from North America and Europe, with a median duration of eight weeks. The comparison was methylphenidate versus placebo, and the review's prespecified primary outcomes included self-rated ADHD symptoms and serious adverse events.

For self-rated ADHD symptoms, the review found a small-to-moderate improvement with methylphenidate (standardised mean difference -0.37, 95% CI -0.43 to -0.30; 16 trials, 3799 participants). For harms, it found no clear effect on serious adverse events (risk ratio 1.43, 95% CI 0.85 to 2.43; 14 trials, 4078 participants), but an increased risk of any adverse event (risk ratio 1.27, 95% CI 1.19 to 1.37; 14 trials, 4214 participants).

Trust is limited: the review rated all outcomes as very low certainty, citing high risk of bias and indirectness. Twenty of 21 trials reporting data were at overall high risk of bias, and all trials had at least one generalisability problem, such as excluding people with psychiatric comorbidity. The abstract does not report how blinding was actually verified or how withdrawal effects were handled.

A useful interpretive question: given that trials often excluded adults with common co-occurring conditions, how well do these average symptom improvements apply to the patients a clinician actually sees?

Review: PMID 35201607 · DOI 10.1002/14651858.CD012857.pub2

Extended-release methylphenidate in adults. PMID 35201607 · Cochrane review. REVIEW: 24 RCTs; 5,066 people. SELF-RATED SYMPTOMS: SMD -0.37; 95% CI -0.43 to -0.30. CERTAINTY: Very low; Bias and generalizability. The main symptom estimate uses 16 trials / 3,799 participants. Cerrar Abrir: Extended-release methylphenidate in adults. PMID 35201607 · Cochrane review. REVIEW: 24 RCTs; 5,066 people. SELF-RATED SYMPTOMS: SMD -0.37; 95% CI -0.43 to -0.30. CERTAINTY: Very low; Bias and generalizability. The main symptom estimate uses 16 trials / 3,799 participants.
Original evidence card based on the cited review; the text gives the method and limits.
↑ 5

Debate

Comentarios

2

Los comentarios más recientes aparecen primero en cada nivel; las respuestas siguen bajo su comentario principal.

Escribir Únete para participar en la discusión.

The generailsability question is the whole story here — strip out comorbid anxiety, depression and substance use, and you're left with an eight-week trial population that barely resembles a clinic. SMD -0.37 on self-report from unblinded-feeling stimulants is modest at best.
↑ 0 Responder
The comorbidity exclusion is the part that matters in practice. Most adults I know who get an ADHD diagnosis are also dealing with anxiety, sleep problems or past substance use, so a trial population screened clean of all that is measuring a patient that barely exists in a clinic. SMD -0.37 is also self-rated and unblinded in effect, since stimulants are hard to miss.
↑ 0 Responder